On Sunday, May 6, Nashville played an important role in the nationwide launch of “All of Us,” the National Institutes of Health’s (NIH) research program that aims to collect the health information of 1 million or more research participants.

A Vanderbilt-led research team has discovered genetic variations that increase the risk of heart attack even when patients are receiving a statin drug like Lipitor or Crestor to lower their blood cholesterol.

The All of Us Research Program, which aims to accelerate the prevention and treatment of illness through precision medicine with the help of a million or more research participants across the United States, officially opens for national enrollment Sunday, May 6.

Four faculty members of Vanderbilt University School of Medicine were among 78 physician-scientists inducted into The American Society for Clinical Investigation (ASCI), an elite honor society of physician-scientists from the upper ranks of academic medicine and industry. They are:

A study led by researchers at Vanderbilt University Medical Center (VUMC) and the University of Arizona College of Pharmacy has generated the first comprehensive catalog of diseases in a single population associated with variations in HLA genes that regulate the body's immune system.

Joshua Denny, M.D., M.S., professor of Biomedical Informatics and associate professor of Medicine at Vanderbilt, has been named to an annual list of the 50 leading experts in health care information technology by Health Data Management, a trade news publication.

Joshua Denny, M.D., M.S., who helped propel Vanderbilt University Medical Center into a leadership role in the national Precision Medicine Initiative, will deliver the next Flexner Discovery Lecture on Thursday, Feb. 4.